基于白细胞介素-2、白细胞介素-10的变化探讨早期梅毒血清固定患者的免疫状态

Abstract
Figure/Table
References (19)
Related Citation (12)

Download: PDF (599 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the changes of interleukin-2(IL-2)and interleukin-10(IL-10)in patients with serum fixation of early syphilis,and to explore the immune status of patients.Methods From January 2017 to January 2019,30 patients with serum fixation of early syphilis in the Department of Dermatology of Huizhou Central People's Hospital were selected as the observation group.Another 30 patients with the negative serological test for syphilis(TURST)after standardized antisyphilitic treatment were the negative conversion group.Another 30 healthy subjects were selected as the control group.The levels of IL-2 and IL-10 in the three groups were compared.Results The IL-2 level in observation group was lower than that in the negative conversion group and control group,and the IL-10 level was higher than that in the negative conversion group and control group,and the differences were statistically significant(P＜0.05).There were no significant differences in IL-2 and IL-10 levels between the negative group and the control group(P＞0.05).Conclusion Patients with serum fixation of early syphilis have some immunosuppression and immune imbalance.In clinical treatment of syphilis,in addition to antibiotics,personalized immune intervention measures should be combined.

Key words： Interleukin-2 Interleukin-10 Early syphilis Serum fixation Immunosuppression Immune imbalance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Qingxiang
	ZENG Mei

Cite this article:

LI Qingxiang,ZENG Mei. Study on immune status of patients with serum fixation of early syphilis based on changes of interleukin-2 and interleukin-10[J]. 中国当代医药, 2022, 29(10): 38-41.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I10/38

[1]	柯吴坚，郑刚，塔依尔·吐尔洪，等.梅毒疫苗研究进展[J].皮肤性病诊疗学杂志，2021，28（3）：228-231.
[2]	Jaiswal AK，Tiwari S，Jamal SB，et al.The pan-genome of Treponema pallidum reveals differences in genome plasticity between subspecies related to venereal and non-venereal syphilis[J].BMC Genomics，2020，21（1）：33.
[3]	靳秀英.我院2016～2017年住院患者梅毒筛查的结果分析[J].中国当代医药，2018，25（22）：152-155.
[4]	Pastuszczak M，Kotnis-Gaska A，Jakubowicz B，et al.Treponema pallidum-specific immune responses and autoimmunity in patients who remain serofast after treatment of syphilis[J].Postepy Dermatol Alergol，2019，36（5）：620-625.
[5]	王龙涛，李海波.免疫调节剂在梅毒血清固定中的应用与展望[J].微量元素与健康研究，2020，37（1）：55-57.
[6]	Magri F，Donà MG，Panetta C，et al.Unusual clinical manifestation and challenging serological interpretation of syphilis：insights from a case report[J].BMC Infect Dis，2021，21（1）：521.
[7]	于晓云，闫宁，李子海，等.CXCL8，CXCL10 和Th1/Th2 细胞因子在神经梅毒患者的血清和脑脊液中的表达情况研究[J].中华男科学杂志，2020，26（4）：335-340.
[8]	Liu LL，Liu WN，Jiang XY，et al.Changes of T lymphocyte subsets in patients with HIV-negative symptomatic neurosyphilis[J].Microb Pathog，2019，130：213-218.
[9]	薛如君，张锡宝.中外最新梅毒指南的解读、比较及更新内容[J].皮肤性病诊疗学杂志，2017，24（1）：52-56.
[10]	Leeyaphan C，Punyaratabandhu P，Jiamton S，et al.Predictors of serological cure after treatment in patients with early syphilis：A retrospective observational study in Thailand[J].Indian J Dermatol Venereol Leprol，2019，85（2）：235.
[11]	张荣，鲁东平，王芬，等.梅毒血清学试验阳性患者血清IL-17、IL-21 水平与TRUST 滴度相关性分析[J].皮肤性病诊疗学杂志，2021，28（1）：7-11.
[12]	程文豪，任虹，胡文龙.梅毒血清固定免疫机制的研究进展[J].实用皮肤病学杂志，2020，13（5）：278-281.
[13]	赵洋，栾兴宝，杜天意，等.梅毒血清固定影响因素及发生机制的研究进展[J].北京医学，2020，42（10）：963-965.
[14]	Qiang D，Wang J，Ci C，et al.Evaluation of serum cytokines to predict serofast in syphilis patients[J].J Infect Chemother，2020，26（9）：970-976.
[15]	贺迎霞，张庆田，王冬梅，等.胸腺五肽联合苄星青霉素对早期梅毒血清固定患者外周血T 淋巴细胞亚群及血清TRUST 转阴率的影响[J].中国性科学，2018，27（11）：115-118.
[16]	廖远泉，廖晖.细胞介导免疫和体液免疫在梅毒“血清固定”致病机制中可能具有免疫病理作用[J].医学争鸣，2016，7（6）：15-17.
[17]	廖远泉.梅毒血清固定相关机制研究进展[J].中华临床实验室管理电子杂志，2018，6（4）：199-203.
[18]	鲁东平，张荣，王芬，等.梅毒血清固定患者NLRP3 炎症小体及细胞因子表达的研究[J].实用医学杂志，2021，37（8）：1041-1045.
[19]	温晶，李珍，赵伟，等.梅毒血清固定患者外周血Th1，Th2，Treg 和Th17 相关细胞因子检测[J].中国麻风皮肤病杂志，2021，37（6）：356-359.